SEC Form 3
FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 05/28/2024 |
3. Issuer Name and Ticker or Trading Symbol
Entera Bio Ltd. [ ENTX ] |
|||||||||||||
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
|
Table I - Non-Derivative Securities Beneficially Owned | |||
---|---|---|---|
1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Ordinary Shares, par value NIS 0.0000769 per share | 75,126(1) | D |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
---|---|---|---|---|---|---|---|
1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
Stock Option (right to buy) | (2) | 01/17/2029 | Ordinary Shares, par value NIS 0.0000769 per share | 20,000 | 3.97 | D | |
Stock Option (right to buy) | (3) | 03/16/2030 | Ordinary Shares, par value NIS 0.0000769 per share | 18,900 | 2.14 | D | |
Stock Option (right to buy) | (4) | 04/07/2031 | Ordinary Shares, par value NIS 0.0000769 per share | 51,000 | 3.61 | D | |
Stock Option (right to buy) | (5) | 04/28/2032 | Ordinary Shares, par value NIS 0.0000769 per share | 45,000 | 2.57 | D | |
Stock Option (right to buy) | (6) | 03/24/2033 | Ordinary Shares, par value NIS 0.0000769 per share | 65,000 | 0.795 | D | |
Stock Option (right to buy) | (7) | 04/19/2034 | Ordinary Shares, par value NIS 0.0000769 per share | 150,000 | 1.99 | D |
Explanation of Responses: |
1. Includes a grant of 25,126 stock-settled restricted stock units. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on April 19, 2024. |
2. The options vest over a four-year period that commenced on January 17, 2019, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period. |
3. The options vest over a four-year period that commenced on March 16, 2020, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period. |
4. The options vest over a four-year period that commenced on April 7, 2021, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period. |
5. The options vest over a four-year period that commenced on April 28, 2022, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period. |
6. The options vest over a four-year period that commenced on April 24, 2023, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period. |
7. The options vest over a three-year period that commenced on April 19, 2024, with 33% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining two-year period. |
Remarks: |
See Exhibit 24.1 - Power of Attorney |
/s/ Dana Yaacov-Garbeli, Attorney-in-fact | 06/07/2024 | |
** Signature of Reporting Person | Date | |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |